Abcam plc (ABCZF)
| Previous Close | 22.25 |
| Open | 22.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 22.25 - 22.25 |
| 52 Week Range | 5.00 - 23.80 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 5.121B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 2,225.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 19, 2020 |
| 1y Target Est | N/A |
- Zacks
Danaher (DHR) Acquires Abcam to Boost Life Sciences Segment
Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
- Reuters
UPDATE 1-Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam, overcoming the initial opposition from the founder of the protein consumables maker. Danaher agreed to buy Abcam in September for $24 per share to expand its portfolio of products and services, but founder Jonathan Milner opposed it saying the offer undervalued the company. Milner, who owns a 6.14% stake, had said he would vote against the acquisition.
- Insider Monkey
Here’s Headwaters Capital’s Perspective on Abcam plc (ABCM) Acquisition
Headwaters Capital Management, an investment management company, released its third-quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined -7.6% (-7.8% net) in the third quarter compared to a -4.7% return for the Russell Mid Cap Index. The YTD results stand at +14.2% (+13.5% net) compared to a +3.9% […]
